Literature DB >> 16447247

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.

Hildrun Haibel1, Martin Rudwaleit, Henning C Brandt, Zarho Grozdanovic, Joachim Listing, Hartmut Kupper, Jürgen Braun, Joachim Sieper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16447247     DOI： 10.1002/art.21563

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  33 in total

1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 2.  Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?

Authors:  M M Ward
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 3.  Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations.

Authors:  Paul E Evans; Darrell S Pardi
Journal:  MedGenMed       Date:  2007-03-19

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 5.  A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.

Authors:  L Goh; A Samanta
Journal:  Rheumatol Int       Date:  2009-06-28       Impact factor: 2.631

Review 6.  Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

Authors:  Carlomaurizio Montecucco
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics.

Authors:  Heiner Appel; Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

8.  Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Kath D Watson; Mark Lunt; Katie McGrother; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2010-05-05       Impact factor: 7.580

9.  The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.

Authors:  Burkhard F Leeb; Elke Böttcher; Hans-Peter Brezinschek; Christoph Czerwenka; Manfred Herold; Hans Hitzelhammer; Franz Mayrhofer; Rudolf Puchner; Franz Rainer; Bernhard Rintelen; Michael Schirmer; Ulrike Stuby; Hans Bröll
Journal:  Clin Rheumatol       Date:  2009-11-11       Impact factor: 2.980

10.  Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.

Authors:  Désirée M van der Heijde; Dennis A Revicki; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Neesha Harnam; Chris Thompson; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.